Study of 5-Fluorouracil and Folinic Acid in Colorectal Cancer
Author Information
Author(s): MJ Mackean, J Cassidy, D Jodrell, J Paul, NS Reed, PA Canney, H Yosef, T Habeshaw, AG Robertson, A McInnes, CJ Twelves
Primary Institution: Beatson Oncology Centre, Glasgow, UK
Hypothesis
Increasing the dose of 5-fluorouracil will improve response rates in patients with advanced colorectal carcinoma.
Conclusion
The study found a low response rate of 18% and a median survival of 7.8 months in patients treated with 5-fluorouracil and folinic acid.
Supporting Evidence
- The overall response rate was 18% with a complete response of 6% and partial response of 12%.
- Overall median survival was 34 weeks with no significant difference between the two cohorts.
- Poor performance status and elevated initial WBC were associated with reduced survival.
Takeaway
Doctors tested a medicine to help people with a type of cancer, but not many got better, and most lived for about 8 months.
Methodology
The study used a group sequential design to evaluate two dose levels of 5-fluorouracil and folinic acid in patients with advanced colorectal carcinoma.
Potential Biases
The cohorts were not randomized, which may introduce selection bias.
Limitations
The study was not randomized and had a relatively low response rate.
Participant Demographics
Patients had advanced colorectal cancer, with a median age of 63 years and similar demographic features across cohorts.
Statistical Information
P-Value
0.27
Confidence Interval
95% CI 30-39 weeks
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website